CalciMedica (CALC) Director Evgeny Zaytsev Receives Derivative Awards

What Happened

• Evgeny Zaytsev, a director of CalciMedica, received grants/acquisitions of derivative securities on 2026-08-19 covering a total of 2,910,534 shares (two grants of 1,450,267 each plus one grant of 10,000). Each line is reported as acquired at $0.00 (derivative instruments), not an open-market stock purchase or sale. These are awards of warrants/options/other derivatives rather than immediate common-stock purchases.

Key Details

• Transaction date: August 19, 2026; Form 4 filed August 21, 2026 (timely filing).
• Instruments: Derivative awards recorded at $0.00 acquisition price; total reported coverage = 2,910,534 shares.
• Exercise windows (per footnotes): one warrant exercisable on/after Aug 19, 2026 and on or prior to the earlier of Dec 25, 2027 or 30 days after public FDA IND clearance for CM5480 (with a 9.99% ownership cap); another warrant exercisable on/after Aug 19, 2026 and through June 25, 2031 (same ~9.99% cap mechanics).
• Source/approval: Securities were issued pursuant to a June 23, 2026 Securities Purchase Agreement (closing June 25, 2026) approved by an independent board committee (F1).
• Holdings structure: Some securities are held by Bering Partners II, L.P.; Bering II GP and the reporting person are listed as having potential voting/dispositive power but disclaim beneficial ownership except for pecuniary interest (F3).
• Vesting: One grant includes an option with 1/12th of shares vesting monthly over one year and full vesting by the 2027 annual meeting (F5).
• Shares owned after transaction: Not specified in the provided filing excerpts.

Context

• These are derivative awards (warrants/options) — they give the right to acquire common shares under specified exercise windows and caps; they are not immediate sales of common stock. Exercise may be limited by an ownership cap (9.99%, adjustable by notice).
• For retail investors: such awards are common for directors and reflect compensation or investment arrangements; they do not by themselves indicate immediate buying or selling of common shares until exercised.